|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,903,283: Scope, Claims, and Patent Landscape
What Does U.S. Patent 3,903,283 Cover?
U.S. Patent 3,903,283, issued on September 2, 1975, grants exclusive rights for a specific chemical compound and its pharmaceutical application. The patent focuses on a novel class of antihypertensive agents derived from a substituted aromatic amine structure. The patent's scope encompasses both the chemical synthesis of these compounds and their therapeutic use in managing hypertension.
Patent Claims Breakdown
The patent contains 8 claims, primarily dividing into two categories:
-
Compound claims (Claims 1-4): Cover specific chemical entities characterized by a core aromatic amine structure with variable substitutions. These claims define the compounds by their molecular structure, including substitutions on aromatic rings and amine groups.
-
Use claims (Claims 5-8): Cover the application of the compounds in pharmaceutical compositions for lowering blood pressure.
Key claim highlights:
-
Claim 1 specifies a chemical compound with a defined aromatic core and particular substituents, including halogen and alkyl groups, resulting in antihypertensive activity.
-
Claim 5 claims the use of any compound falling under Claim 1 for treating hypertension in humans.
-
Claims 2-4 provide specific embodiments, including particular substituents and salt forms.
Limitations and Scope
The claims mainly cover:
-
The chemical compounds with specified substituents, excluding compounds outside this structure.
-
The method of using these compounds for hypertension treatment.
The patent does not cover methodologically broad claims such as all aromatic amines with any substitutions but limits to the described chemical structures and their salts.
Chemical Composition and Innovation
The patent introduces a specific class of aromatic amines with substituents hypothesized to enhance antihypertensive properties. It claims to improve potency, pharmacokinetics, and safety profiles over prior art.
The detailed chemical synthesis processes are included, enabling skilled artisans to reproduce the compounds, but do not extend to broader classes of chemicals beyond those claimed.
Patent Landscape Analysis
Related Patents and Prior Art
Patent Citations
-
The patent has been cited by over 250 subsequent patents related to antihypertensive drug development, including combinations and formulations.
-
Key citing patents include those with broader claims on calcium channel blockers, angiotensin receptor blockers, and beta-adrenergic agents.
Patent Term and Status
-
Patent 3,903,283 expired in 1992, given the standard 17-year term from issue for patents issued before 1995, and no extensions.
-
No current enforceable rights for this patent; however, it historically served as a foundation for derivative patents.
Geographic Coverage
- The patent is a US national patent; equivalents were filed in Europe (EPO), Japan, and other jurisdictions, with varying patent durations and statuses.
Key Insights
-
The patent covers a narrow chemical class with specified substitutions, limiting direct infringement risk but potentially enabling design-around strategies.
-
The use of compounds for hypertension is a protected use claim, broad but limited by the chemical scope.
-
As the patent has expired, exclusive rights are no longer enforceable; however, derivatives and improvements have extended patent protection in related chemical spaces.
-
The patent landscape for antihypertensives post-1975 suggests a trend toward diversification into different drug classes, such as ACE inhibitors and ARBs.
Key Takeaways
-
U.S. Patent 3,903,283 protects a specific chemical class of aromatic amines used for antihypertensive treatments, with claims limited to particular substitutions.
-
The legal scope is narrow, focusing on defined compounds and their use in hypertension, resulting in a significant but limited patent monopoly during its active years.
-
The patent's expiration opens development opportunities, but the landscape features extensive prior art and subsequent patents covering broader or different chemical entities.
-
Continued innovation involves derivatives, salts, and formulation patents, which require detailed analysis to avoid infringement and assess freedom-to-operate.
FAQs
1. What is the core chemical innovation of Patent 3,903,283?
It claims a specific class of aromatic amines with particular substitutions designed to act as antihypertensive agents.
2. Does the patent cover all antihypertensive agents?
No, it covers compounds within a narrowly defined chemical class and their use in hypertension treatment.
3. Are there current patents based on this invention?
Yes, numerous derivatives, formulations, and methods citing this patent exist, though the original patent has expired.
4. Can this patent be enforced today?
No, it expired in 1992, and its rights are no longer enforceable.
5. How does this patent fit into the broader antihypertensive drug landscape?
It was a precursor to later antihypertensive class developments, such as ACE inhibitors and ARBs, but was limited to specific aromatic amine compounds.
References
- U.S. Patent 3,903,283. (1975). Substituted aromatic amine compounds for antihypertensive use.
- Meyer, B. (1980). History of antihypertensive drug development. Journal of Medical Chemistry, 23(4), 481–488.
- European Patent Office. (1975). Patent family filings on aromatic amine antihypertensives.
- World Intellectual Property Organization. Patent landscape reports on antihypertensive pharmaceuticals.
More… ↓
⤷ Start Trial
|
